Your browser doesn't support javascript.
loading
Correction to: Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.
Mörén, Lina; Perryman, Richard; Crook, Tim; Langer, Julia K; Oneill, Kevin; Syed, Nelofer; Antti, Henrik.
Afiliação
  • Mörén L; Department of Chemistry, Umeå University, SE 901 87, Umeå, Sweden.
  • Perryman R; John Fulcher Neuro-Oncology Laboratory, Imperial College London, London, UK.
  • Crook T; St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, Surrey, UK.
  • Langer JK; John Fulcher Neuro-Oncology Laboratory, Imperial College London, London, UK.
  • Oneill K; John Fulcher Neuro-Oncology Laboratory, Imperial College London, London, UK.
  • Syed N; John Fulcher Neuro-Oncology Laboratory, Imperial College London, London, UK. n.syed@imperial.ac.uk.
  • Antti H; Department of Chemistry, Umeå University, SE 901 87, Umeå, Sweden. henrik.antti@umu.se.
BMC Cancer ; 18(1): 268, 2018 03 08.
Article em En | MEDLINE | ID: mdl-29519248
ABSTRACT
In the original publication of this article [1], published on 8 February 2018, it was noticed that the acknowledgement of the source of the drug ADI-PEG20 was missing.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article